|
- Enzalutamide–Talazoparib Combo for Advanced Prostate Cancer
Men with metastatic castration-resistant prostate cancer may live longer if they receive initial treatment with enzalutamide (Xtandi) combined with talazoparib (Talzenna) rather than enzalutamide alone, updated results from a large clinical trial show
- Unlocking Tomorrows Prostate Cancer Treatments
As we venture further into 2025, treatments like Talzenna at UCI demonstrate the potential of combining cutting-edge research with compassionate care, ensuring a hopeful future for those combatting metastatic prostate cancer
- Combination Therapy Shows Promise for Metastatic Prostate Cancer
Home » News » Combination Therapy Shows Promise for Metastatic Prostate Cancer Updated findings from the TALAPRO-2 clinical trial reveal that combining talazoparib (Talzenna) and enzalutamide (Xtandi) as an initial treatment for metastatic castration-resistant prostate cancer (mCRPC) significantly improves survival compared to enzalutamide alone
- Pfizer’s TALZENNA® in Combination with XTANDI® Improves Survival . . .
TALZENNA + XTANDI is the first PARP inhibitor plus ARPI combination to demonstrate statistically significant and clinically meaningful improvement in overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) regardless of HRR mutation status TALZENNA + XTANDI improved median OS by almost 9 months in unselected patients (Cohort 1) and by 14 months in
- Early data shows talazoparib improves prostate cancer survival
The oral drug talazoparib (Talzenna) plus standard treatment improved survival of metastatic prostate cancer patients, especially those with DNA repair mutations
- Talazoparib (Talzenna) Plus Enzalutamide (Xtandi) Improves Survival in . . .
The combination of talazoparib and enzalutamide improves overall survival compared with enzalutamide alone in patients with metastatic castration-resistant prostate cancer, with a more pronounced benefit observed in those with homologous recombination repair gene alterations, phase 3 data show
- Talzenna Plus Xtandi Shows Significant Overall Survival Improvement in . . .
Talzenna (talazoparib) with Xtandi (enzalutamide) produced a statistically significant improvement in overall survival among patients with metastatic castration-resistant prostate cancer, regardless of mutation status, making it the first combination of a PARP inhibitor and ARPI to achieve these results
- Pfizers Talzenna tees up 3-way PARP battle in prostate cancer
Adding Talzenna to Pfizer and Astellas’ androgen receptor inhibitor Xtandi significantly staved off tumor progression or death in patients with metastatic castration-resistant prostate cancer
|
|
|